News

September 9, 2021

Entering Next Generation of Targeted Protein Degradation

E3 Ligases are important components of the Ubiquitin Proteasome System (UPS), the master regulator of protein homeostasis that is essential for proper cellular function. The total number of these enzymes being estimated at 600 or more. Recently, only a handful of the E3 ligases have been applied into protein degrader drug design.

 

AnHorn Medicines, as one of the innovators in the field of Targeted Protein Degradation, we have commitment to identify novel E3 enzymes with a clear disease involvement to expand our target coverage.

 

The exploration of novel E3 ligases requires a wide range data analysis, virtual design, and scientific validations. The efforts are supposed to be knowledge and labor-intensive. For now, we have built an automatic approach with the leverage of machine learning and AI, we are able to largely expand protein degrader programs and generate better therapeutic agents to unmet needs.

 

 

AnHorn Medicines vision ourselves a shed of light in biotechnology, we are turning innovation to new therapeutics, and creating new opportunities to target difficult-to-treat diseases through our technology.

June 3, 2024
AnHorn Medicines to Present AI-Driven Drug Discovery in Protein Degradation at NVIDIA AI Summit in Taiwan
May 15, 2023
AnHorn Medicines Presents Research of Novel Protein Degrader for Topical Use at ISID Meeting 2023
Scroll to Top